Mentions:
1: Baroness Barker (LD - Life peer) and the All-Party Parliamentary Group on Sexual and Reproductive Health. - Speech Link
2: Baroness Merron (Lab - Life peer) a new 10-year sexual and reproductive health strategy to address infections in the long term. - Speech Link
Report Jan. 25 2024
Committee: International Development Committee (Department: Department for International Development)Found: First Report - The FCDO’s approach to sexual and reproductive health HC 108 Report
Special Report May. 17 2024
Committee: International Development Committee (Department: Department for International Development)Found: Third Special Report - The FCDO’s approach to sexual and reproductive health: Government Response to
Mar. 04 2024
Source Page: UK supports most vulnerable women and girls in UkraineFound: UK supports most vulnerable women and girls in Ukraine
Mar. 04 2024
Source Page: UK supports most vulnerable women and girls in UkraineFound: UK supports most vulnerable women and girls in Ukraine
Asked by: Dan Carden (Labour - Liverpool, Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much her Department plans to allocate to the Reproductive Health, Sexual Health and HIV Innovation Fund in the 2024-25 financial year.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Reproductive Health, Sexual Health and HIV Innovation Fund is a competitive grant scheme first started by Public Health England (PHE) which aimed to encourage local innovation to reduce the impact of HIV and improve sexual and reproductive health in England, with the first four cohorts addressing HIV only. The following table outlines the funding received for the seven cohorts which have taken place since the scheme began:
Year | Funding (£) |
2015/2016 (Cohort 1) | 501,463 |
2016/2017 (Cohort 2) | 629,844 |
2017/2018 (Cohort 3) | 574,030 |
2018/2019 (Cohort 4) | 603,418 |
2019/2020 (Cohort 5) | 605,102 |
2020/2021 (Cohort 6) | 301,764 |
2021/2022 (Cohort 7) | 290,129 |
Funding was paused for 2022/2023 to allow for the publication of an independent review. In January 2023, Ipsos Mori published the findings from an overarching independent impact evaluation of the Innovation Fund which is available at the following link:
No funding was provided for 2023/2024, and a decision has not yet been made regarding funding for 2024/2025.
Asked by: Dan Carden (Labour - Liverpool, Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much her Department has allocated to the Reproductive Health, Sexual Health and HIV Innovation Fund in the 2023-24 financial year.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Reproductive Health, Sexual Health and HIV Innovation Fund is a competitive grant scheme first started by Public Health England (PHE) which aimed to encourage local innovation to reduce the impact of HIV and improve sexual and reproductive health in England, with the first four cohorts addressing HIV only. The following table outlines the funding received for the seven cohorts which have taken place since the scheme began:
Year | Funding (£) |
2015/2016 (Cohort 1) | 501,463 |
2016/2017 (Cohort 2) | 629,844 |
2017/2018 (Cohort 3) | 574,030 |
2018/2019 (Cohort 4) | 603,418 |
2019/2020 (Cohort 5) | 605,102 |
2020/2021 (Cohort 6) | 301,764 |
2021/2022 (Cohort 7) | 290,129 |
Funding was paused for 2022/2023 to allow for the publication of an independent review. In January 2023, Ipsos Mori published the findings from an overarching independent impact evaluation of the Innovation Fund which is available at the following link:
No funding was provided for 2023/2024, and a decision has not yet been made regarding funding for 2024/2025.
Asked by: Dan Carden (Labour - Liverpool, Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the findings were of the independent review of the impact of the Sexual Health, Reproductive Health and HIV Innovation Fund.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Reproductive Health, Sexual Health and HIV Innovation Fund is a competitive grant scheme first started by Public Health England (PHE) which aimed to encourage local innovation to reduce the impact of HIV and improve sexual and reproductive health in England, with the first four cohorts addressing HIV only. The following table outlines the funding received for the seven cohorts which have taken place since the scheme began:
Year | Funding (£) |
2015/2016 (Cohort 1) | 501,463 |
2016/2017 (Cohort 2) | 629,844 |
2017/2018 (Cohort 3) | 574,030 |
2018/2019 (Cohort 4) | 603,418 |
2019/2020 (Cohort 5) | 605,102 |
2020/2021 (Cohort 6) | 301,764 |
2021/2022 (Cohort 7) | 290,129 |
Funding was paused for 2022/2023 to allow for the publication of an independent review. In January 2023, Ipsos Mori published the findings from an overarching independent impact evaluation of the Innovation Fund which is available at the following link:
No funding was provided for 2023/2024, and a decision has not yet been made regarding funding for 2024/2025.
Asked by: Dan Carden (Labour - Liverpool, Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much her Department has provided for the HIV Innovation Fund in each year since 2015.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Reproductive Health, Sexual Health and HIV Innovation Fund is a competitive grant scheme first started by Public Health England (PHE) which aimed to encourage local innovation to reduce the impact of HIV and improve sexual and reproductive health in England, with the first four cohorts addressing HIV only. The following table outlines the funding received for the seven cohorts which have taken place since the scheme began:
Year | Funding (£) |
2015/2016 (Cohort 1) | 501,463 |
2016/2017 (Cohort 2) | 629,844 |
2017/2018 (Cohort 3) | 574,030 |
2018/2019 (Cohort 4) | 603,418 |
2019/2020 (Cohort 5) | 605,102 |
2020/2021 (Cohort 6) | 301,764 |
2021/2022 (Cohort 7) | 290,129 |
Funding was paused for 2022/2023 to allow for the publication of an independent review. In January 2023, Ipsos Mori published the findings from an overarching independent impact evaluation of the Innovation Fund which is available at the following link:
No funding was provided for 2023/2024, and a decision has not yet been made regarding funding for 2024/2025.
Asked by: Baroness Northover (Liberal Democrat - Life peer)
Question to the Foreign, Commonwealth & Development Office:
To ask His Majesty's Government what steps they are taking to achieve universal access to sexual and reproductive health and rights as per Sustainable Development Goal target 5.6.
Answered by Lord Benyon - Minister of State (Foreign, Commonwealth and Development Office)
The White Paper on International Development reaffirmed the UK's commitment to deploy policy and investment to advance and strongly defend universal access to comprehensive Sexual and Reproductive Health and Rights (SRHR) in line with Sustainable Development Goal target 5.6.
The UK Government is committed to driving progress and demonstrating leadership on SRHR globally as a major donor, through our diplomatic network and in collaboration with partners. For example, the UNFPA Supplies Partnership averted 8 million unintended pregnancies, 2.2 million unsafe abortion and 170,000 maternal and child deaths in 2022, with the UK as their largest donor. The Women's Integrated Sexual Health (WISH) Programme supported 9.5 million women to use modern methods of contraception and averted over 45,000 maternal deaths, 5 million unsafe abortions and over 16 million unintended pregnancies from the programme's inception to 2021. In May 2023, the UK joined other G7 leaders in re-asserting the critical role of comprehensive SRHR in our efforts to achieve gender equality, explicitly recognising the need for access to safe and legal abortion as well as post abortion care.